Download PPT - Altogen Biosystems

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Secreted frizzled-related protein 1 wikipedia , lookup

Cre-Lox recombination wikipedia , lookup

Molecular cloning wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

DNA vaccination wikipedia , lookup

Cell culture wikipedia , lookup

Transformation (genetics) wikipedia , lookup

List of types of proteins wikipedia , lookup

Channelrhodopsin wikipedia , lookup

Cell-penetrating peptide wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Transcript
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
Altogen Biosystems offers the MG-63 Transfection Reagent
among a host of 100+ cell line specific In Vitro Transfection Kits.
The MG-63 Transfection Reagent is an advanced formulation of a
lipid based reagent, and it has been developed to provide high
transfection efficiency with the MG-63 cell line.
This cell line is an excellent transfection host and can be useful in
a wide array of biomedical applications. When cultured in vitro,
MG-63 cells are a monolayer and adhere to the surface of the
culture flask.
Other applications include drug discovery, gene expression
studies, molecular and cell biology research applications.
Purchase MG-63 Transfection Kit at www.Altogen.com
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
MG-63 Cell Line Description and Applications
High Density MG-63 cells
www.lonza.com
The MG-63 cell line originates from the bone
tissue from a 14-year-old Caucasian male with
osteosarcoma. The cell line is hypotriploid and has
a modal chromosome number of 66. The MG-63
cell line displays fibroblast morphology and
express TGF-beta RI and RII (transforming growth
factor beta). The cell line produces high levels of
interferon with stimulation. The interferon is
induced via cycloheximide, actinomycin D and
polyinosinic-polycytidylic acid. The MG-63 cell line
is an effective transfection host and has
applications in a wide array in the biomedical field.
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
MG-63 Transfection Protocol
1. Plate 10,000 - 15,000 MG-63 cells per well in 0.5 ml of complete growth medium 12–24 hours prior to
transfection
2. Wash with 1xPBS and add 0.5 ml of fresh growth medium
3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent,
and
• 750 ng DNA (or mRNA), or
• 30 nM - 50 nM of siRNA (or microRNA)
*Referred to a final volume including growth medium
4. Incubate transfection complexes at RT for 15 - 30 minutes
5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex,
therefore increasing transfection efficiency; however it may increase cell toxicity
6. Add prepared transfection complexes to 0.5 ml of complete growth medium with MG-63 cells (from
step 2)
7. Incubate cells at 37ºC in a humidified CO2 incubator
8. Assay for phenotype or target gene expression 48 - 72 hours after transfection
Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of
Transfection Enhancer reagent 12-24 hours after transfection
If the viability of MG-63 cells being transfected is affected at 16 - 24 hours post-transfection, the level of
cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to
transfectant
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
General Lipoplex-mediated Transfection Mechanism of Action
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
MG-63 Transfection Kit Product Details
•
Two component formulation enhances lipid mediated transfection efficiency
•
Optimized for intracellular delivery of plasmid DNA, siRNA, microRNA, and mRNA
•
High transfection efficiency of both siRNA and plasmid DNA without compromising cell viability
•
Achieve robust siRNA uptake for dependable gene silencing
•
Effective transfection under conditions of up to 40% serum
•
Transfection kit includes Transfection Enhancer reagent
•
Gentle enough to be used for single cell analysis
Developed and manufactured by Altogen Biosystems (www.Altogen.com)
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
Data
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into MG63 cells
following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for
Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are
normalized to untreated sample. Data are means ± SD (n=4).
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
Data
Figure 2. Protein expression of Lamin A in MG-63 cells. DNA plasmid expressing Lamin A or siRNA targeting
Lamin A were transfected into MG-63 cells following Altogen Biosystems transfection protocol. At 72 hours posttransfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein,
10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Leading Developer and Manufacturer of In Vivo and DNA Transfection
Kits, Transfection Reagents and Electroporation Delivery Products
Products > MG-63
Transfection Reagent (Osteosarcoma, CRL-1427)
MG-63 Transfection Kit Benefits
• Pre-optimized transfection protocol for MG-63 cell line
• Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing
• Free of serum and protein of animal origin
• Compatible with standard and reverse transfection methods (both protocols provided in the kit manual)
• Easy to use MG-63 transfection protocol ensures great performance with expedited experimental timeline
• Equally efficient for single or multiple transfections
• Can be used for transient transfection and development of stable MG-63 cell lines
• Bio-degradable after endocytosis
• Used for preclinical research worldwide
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA
Telephone  702 349 6103  Fax  702 989-0841  email  [email protected]